Finding 1211140 (2022-001)

Material Weakness Repeat Finding
Requirement
A
Questioned Costs
-
Year
2022
Accepted
2026-04-30
Audit: 400353
Organization: Carestl Health (MO)

AI Summary

  • Core Issue: CareSTL Health faced challenges in financial reporting due to unexpected loss of access to audit materials, not due to internal control failures.
  • Impacted Requirements: Key financial processes, including trial balance accuracy and documentation support, were compromised, affecting audit readiness.
  • Recommended Follow-Up: Implement a remediation plan focusing on finalizing trial balances, maintaining reconciliations, and enhancing documentation practices to improve future audits.

Finding Text

CARESTL HEALTH SCHEDULE OF FINDINGS AND QUESTIONED COSTS YEAR ENDED DECEMBER 31, 2022 34 SECTION - FINANCIAL STATEMENTS FINDINGS (Continued) Recommendation We recommend that management implement a comprehensive remediation plan to strengthen financial reporting processes, including: • Ensuring the trial balance is complete, accurate, and finalized prior to audit • Preparing and maintaining reliable rollforward schedules that agree to the general ledger • Performing timely and accurate reconciliations of all key accounts, particularly cash • Establishing procedures to ensure all financial transactions are supported with adequate documentation • Implementing review and approval controls over financial records and reconciliations • Evaluating staffing and resources to ensure the accounting function can meet reporting requirements Strengthening these areas is critical to improving the accuracy, reliability, and auditability of the organization’s financial statements. Management Response Management respectfully disagrees with the characterization that the financial statements finding reflects a material weakness in CareSTL Health’s internal controls or financial reporting processes. The conditions described in the finding were not the result of inadequate accounting practices or lack of oversight, but rather the direct consequence of an abrupt and unexpected disruption outside the organization’s control. Specifically, CareSTL Health was suddenly and without notice shut out of the audit portal maintained by the previous auditor, which immediately terminated our access to all fieldwork, schedules, reconciliations, and supporting documentation that had been prepared by the external consultant accounting group working with that auditor. This included months of work product, trial balance support, rollforward schedules, reconciliations, and documentation that had already been compiled for audit readiness. When access was revoked, all consultant prepared materials were lost, and the organization was forced to reconstruct audit support from scratch. This loss of access—not a failure of internal controls—resulted in the incomplete or inconsistent schedules observed at the start of the audit. The organization was not given sufficient time to rebuild the documentation that had already existed and had been prepared for the prior audit team. The disruption was compounded by staffing shortages, reimbursement only funding constraints, and overlapping federal deadlines, all of which limited the organization’s ability to rapidly recreate the lost materials. CARESTL HEALTH SCHEDULE OF FINDINGS AND QUESTIONED COSTS YEAR ENDED DECEMBER 31, 2022 35 SECTION - FINANCIAL STATEMENTS FINDINGS (Continued) Despite these challenges, CareSTL Health maintains internal controls, accounting processes, and reconciliation procedures consistent with GAAP and the COSO framework. The organization performs routine reconciliations, maintains supporting documentation, and follows established financial reporting practices. Had the prior auditor not terminated access to the audit portal and consultant workpapers, the financial records would have been complete, accurate, and audit ready at the commencement of fieldwork. Management agrees with the recommendations provided and has already begun implementing enhancements to strengthen financial reporting and audit readiness, including: ▪ Ensuring the trial balance is finalized prior to audit ▪ Maintaining roll forward schedules that reconcile to the general ledger ▪ Performing timely and accurate reconciliations of all key accounts ▪ Strengthening documentation retention and support for all transactions ▪ Implementing review and approval controls over financial records ▪ Evaluating staffing and resources to ensure adequate accounting capacity These improvements, combined with the corrective actions outlined in our HRSA financial management response, will ensure that future audits proceed efficiently and that all required documentation is readily available.

Corrective Action Plan

Recommendation We recommend that management implement a comprehensive remediation plan to strengthen financial reporting processes, including: • Ensuring the trial balance is complete, accurate, and finalized prior to audit • Preparing and maintaining reliable rollforward schedules that agree to the general ledger • Performing timely and accurate reconciliations of all key accounts, particularly cash • Establishing procedures to ensure all financial transactions are supported with adequate documentation • Implementing review and approval controls over financial records and reconciliations • Evaluating staffing and resources to ensure the accounting function can meet reporting requirements Strengthening these areas is critical to improving the accuracy, reliability, and auditability of the organization’s financial statements.

Categories

Internal Control / Segregation of Duties Cash Management Material Weakness Reporting

Other Findings in this Audit

  • 1211105 2022-001
    Material Weakness Repeat
  • 1211106 2022-002
    Material Weakness Repeat
  • 1211107 2022-003
    Material Weakness Repeat
  • 1211108 2022-004
    Material Weakness Repeat
  • 1211109 2022-005
    Material Weakness Repeat
  • 1211110 2022-001
    Material Weakness Repeat
  • 1211111 2022-002
    Material Weakness Repeat
  • 1211112 2022-003
    Material Weakness Repeat
  • 1211113 2022-004
    Material Weakness Repeat
  • 1211114 2022-005
    Material Weakness Repeat
  • 1211115 2022-001
    Material Weakness Repeat
  • 1211116 2022-002
    Material Weakness Repeat
  • 1211117 2022-003
    Material Weakness Repeat
  • 1211118 2022-004
    Material Weakness Repeat
  • 1211119 2022-005
    Material Weakness Repeat
  • 1211120 2022-001
    Material Weakness Repeat
  • 1211121 2022-002
    Material Weakness Repeat
  • 1211122 2022-003
    Material Weakness Repeat
  • 1211123 2022-004
    Material Weakness Repeat
  • 1211124 2022-005
    Material Weakness Repeat
  • 1211125 2022-001
    Material Weakness Repeat
  • 1211126 2022-002
    Material Weakness Repeat
  • 1211127 2022-003
    Material Weakness Repeat
  • 1211128 2022-004
    Material Weakness Repeat
  • 1211129 2022-005
    Material Weakness Repeat
  • 1211130 2022-001
    Material Weakness Repeat
  • 1211131 2022-002
    Material Weakness Repeat
  • 1211132 2022-003
    Material Weakness Repeat
  • 1211133 2022-004
    Material Weakness Repeat
  • 1211134 2022-005
    Material Weakness Repeat
  • 1211135 2022-001
    Material Weakness Repeat
  • 1211136 2022-002
    Material Weakness Repeat
  • 1211137 2022-003
    Material Weakness Repeat
  • 1211138 2022-004
    Material Weakness Repeat
  • 1211139 2022-005
    Material Weakness Repeat
  • 1211141 2022-002
    Material Weakness Repeat
  • 1211142 2022-003
    Material Weakness Repeat
  • 1211143 2022-004
    Material Weakness Repeat
  • 1211144 2022-005
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.527 GRANTS FOR NEW AND EXPANDED SERVICES UNDER THE HEALTH CENTER PROGRAM $5.67M
93.224 HEALTH CENTER PROGRAM $4.13M
93.526 GRANTS FOR CAPITAL DEVELOPMENT IN HEALTH CENTERS $0
93.778 GRANTS TO STATES FOR MEDICAID $0